Latest news with #EquityRule
Yahoo
4 days ago
- Business
- Yahoo
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the 'Panel') indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the 'Bid Price Rule'). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the 'Equity Rule') by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@
Yahoo
03-04-2025
- Business
- Yahoo
Aptose Biosciences shares to delist from Nasdaq as of April 2
Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the Company from The Nasdaq Stock Market. Under the terms of the Panel's December 17, decision in this matter, the Company was required to demonstrate compliance with the Exchange's equity requirement in Listing Rule 5550(b)(1) on or before March 31. As indicated in the Decision, March 31st represented the full extent of the Panel's discretion to grant continued listing while the Company was non-compliant with the Equity Rule. On March 31, through its advisor, the Company confirmed that it had been unable to regain compliance with the Equity Rule by that date. Accordingly, the Panel has determined to delist the Company's common shares from Nasdaq and will suspend trading in those securities effective at the open of business on April 2, 2025. The Company and board will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national Securities Exchange at the appropriate time. Aptose's shares remain listed on TSX under the symbol 'APS'. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APTO: Disclaimer & DisclosureReport an Issue Aptose Biosciences: Promising Clinical Progress and Strategic Collaborations Justify Buy Rating Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright Aptose Biosciences Advances AML Therapy and Strengthens Financial Position Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year Aptose Biosciences (APTO) Q4 Earnings Cheat Sheet Sign in to access your portfolio
